Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
16 July 2020Website:
http://www.relaytx.comNext earnings report:
21 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 21 Nov 2024 00:59:54 GMTDividend
Analysts recommendations
Institutional Ownership
RLAY Latest News
The heavy selling pressure might have exhausted for Relay Therapeutics (RLAY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Relay Therapeutics (RLAY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
The biotech firmed up the details of its upcoming secondary share issue. However, the flotation will be dilutive to existing shareholders.
CAMBRIDGE, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today the pricing of an underwritten public offering of 28,571,429 shares of its common stock at a public offering price of $7.00 per share.
RLAY stock soars on positive interim efficacy data from the early-stage study of its doublet therapy, RLY-2608 in combination with Faslodex, for treating MBC.
CAMBRIDGE, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today that it has commenced an underwritten public offering of $200 million of shares of its common stock.
U.S. stocks traded higher toward the end of trading, with the S&P 500 gaining around 1% on Monday.
3 new programs include 2 genetic disease programs – vascular malformations & Fabry disease – & 1 precision oncology program – NRAS-specific inhibitor Cash guidance remains unchanged, and is expected to fund operations into second half of 2026 Relay Therapeutics to host webcast event today, June 6, at 8:00 a.m. ET CAMBRIDGE, Mass.
Relay Therapeutics, Inc. (RLAY) reported a quarterly loss of $0.62 per share, which was lower than the expected loss of $0.70 per share according to the Zacks Consensus Estimate. This is an improvement from the loss of $0.78 per share reported in the same quarter last year.
Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company, will be participating in three upcoming fireside chats, including the Stifel 2024 Virtual Targeted Oncology Forum on April 17, 2024 at 1:00 p.m.
- 1(current)
What type of business is Relay Therapeutics?
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
What sector is Relay Therapeutics in?
Relay Therapeutics is in the Healthcare sector
What industry is Relay Therapeutics in?
Relay Therapeutics is in the Biotechnology industry
What country is Relay Therapeutics from?
Relay Therapeutics is headquartered in United States
When did Relay Therapeutics go public?
Relay Therapeutics initial public offering (IPO) was on 16 July 2020
What is Relay Therapeutics website?
https://www.relaytx.com
Is Relay Therapeutics in the S&P 500?
No, Relay Therapeutics is not included in the S&P 500 index
Is Relay Therapeutics in the NASDAQ 100?
No, Relay Therapeutics is not included in the NASDAQ 100 index
Is Relay Therapeutics in the Dow Jones?
No, Relay Therapeutics is not included in the Dow Jones index
When was Relay Therapeutics the previous earnings report?
No data
When does Relay Therapeutics earnings report?
The next expected earnings date for Relay Therapeutics is 21 February 2025